Trial Profile
A pilot study using the new antiemetic netupitant and palonosetron (Akynzeo) in patients with melphalan associated nausea and vomiting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2018
Price :
$35
*
At a glance
- Drugs Netupitant/palonosetron (Primary) ; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 26 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association